On Invalid Date, Collplant Biotechnologies (NASDAQ: CLGN) reported Q2 2023 earnings per share (EPS) of $0.51, up 230.77% year over year. Total Collplant Biotechnologies earnings for the quarter were $5.76 million. In the same quarter last year, Collplant Biotechnologies's earnings per share (EPS) was -$0.39.
As of Q3 2023, Collplant Biotechnologies's earnings has grown year over year. Collplant Biotechnologies's earnings in the past year totalled -$6.73 million.
What was CLGN's revenue last quarter?
On Invalid Date, Collplant Biotechnologies (NASDAQ: CLGN) reported Q2 2023 revenue of $10.18 million up 15,330.3% year over year. In the same quarter last year, Collplant Biotechnologies's revenue was $66.00 thousand.
What was CLGN's revenue growth in the past year?
As of Q3 2023, Collplant Biotechnologies's revenue has grown 1,752.92% year over year. This is 1,651.05 percentage points higher than the US Biotechnology industry revenue growth rate of 101.87%. Collplant Biotechnologies's revenue in the past year totalled $10.78 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.